C. Sheen

发表

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.

D. Teachey, C. Sheen, J. Hall, 2008, Blood.

acute lymphoblastic leukemia Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like

M. Loh, D. Teachey, C. Sheen, 2012 .

combination to treat acute lymphoblastic leukemia mTOR inhibitors are synergistic with methotrexate: an effective

D. Teachey, C. Sheen, T. Ryan, 2013 .

Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study.

D. Teachey, C. Sheen, A. Seif, 2010, Blood.

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

D. Wechsler, E. Rappaport, K. Sullivan, 2009, British journal of haematology.

Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.

D. Teachey, C. Sheen, V. Brown, 2007, Cancer research.

disease Targeting Notch signaling in autoimmune and lymphoproliferative

C. Sheen, T. Ryan, V. Brown, 2013 .

Targeting Notch signaling in autoimmune and lymphoproliferative disease.

D. Teachey, C. Sheen, J. Hall, 2008, Blood.

Neuropeptides activate human mast cell degranulation and chemokine production

C. Sheen, M. Kulka, R. Schleimer, 2008 .

Neuropeptides activate human mast cell degranulation and chemokine production.

C. Sheen, M. Kulka, R. Schleimer, 2006, Immunology.

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

M. Loh, D. Teachey, C. Sheen, 2012, Blood.

Targeting JAK 1 / 2 and mTOR in Murine Xenograft Models of Ph-like Acute Lymphoblastic Leukemia ( ALL )

M. Loh, D. Teachey, C. Sheen, 2012 .